<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664595</url>
  </required_header>
  <id_info>
    <org_study_id>55-213-08-1-2</org_study_id>
    <nct_id>NCT04664595</nct_id>
  </id_info>
  <brief_title>Requirements of Propofol With Target Controlled Infusions for Supraglottic Airway Devices</brief_title>
  <official_title>Requirements of Propofol With Target Controlled Infusions for Supraglottic Airway Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      to evaluate and compare the effect-site concentration of propofol with the TCI system for&#xD;
      second-generation SGA device insertion between the I-gel™, Supreme™, ProSeal™ and Laryngeal&#xD;
      Tube Suction II™.&#xD;
&#xD;
      to determine the hemodynamic changes during insertion of supraglottic devices in patients&#xD;
      undergoing elective surgery and any complications after device insertion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators enrolled ASA physical status I-III patients who were 18-70 years old and&#xD;
      scheduled for general anesthesia for elective non-cardiac surgery with SGA devices.Adults&#xD;
      with a potentially difficult airway (cervical spine disease, Mallampati classification IV, or&#xD;
      a mouth opening less than 2.5 cm.), reactive airway disease, signs of respiratory infection&#xD;
      or a plan to remain intubated were excluded from the study. The investigators also excluded&#xD;
      patients who had a risk of gastric aspiration or morbid obesity (body mass index &gt; 35 kg/m2).&#xD;
&#xD;
      Patients were randomized into 4 groups (I-gel™, Supreme™, ProSeal™ and Laryngeal Tube Suction&#xD;
      II™ SGAs) according to a computer generated randomization list and patients were allocated&#xD;
      consecutively. The sample size of each group required 10 patients.&#xD;
&#xD;
      All patients were pre-oxygenated with 100% oxygen. After the administration of 2 µg/ml&#xD;
      intravenous fentanyl for 5 minutes, anesthesia was induced with the Schnider pharmacokinetic&#xD;
      TCI system. After equilibration of the plasma-site and effect-site concentrations in propofol&#xD;
      TCI, 1 of the 4 types of SGA was randomly inserted by two anesthesiologists (resident trainee&#xD;
      and staff doctor) who were unaware of the actual plasma concentration of propofol without the&#xD;
      use of a muscle relaxant.&#xD;
&#xD;
      The response of each patient determined the effect-site concentration of propofol of the next&#xD;
      patient. &quot;No Response&quot; was defined as Laryngeal Mask Airway Insertion Score = 0 and&#xD;
      &quot;Response&quot; was defined as Laryngeal Mask Airway Insertion Score ≥ 1. If the insertion of the&#xD;
      supraglottic airway device was successful (&quot;No Response&quot;), then the target effect-site&#xD;
      concentration was decreased by a step of 0.4 µg/ml. If the insertion failed (&quot;Response&quot;), the&#xD;
      target effect-site concentration was increased by the same dose. The patients' responses to&#xD;
      LMA insertion was classified by blinded investigators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>4 second generation of supraglottic airway device</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of propofol for supragloqtic airway devices insertion</measure>
    <time_frame>2 years</time_frame>
    <description>The effect-site concentration of propofol required to insert supraglottic airway devices.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure changes from baseline after insertion of supraglottic devices</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Appropriate Affect</condition>
  <condition>Complication of Device Insertion</condition>
  <arm_group>
    <arm_group_label>Group SP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The Supreme™ group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group PS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The ProSeal™ group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The I-gel™ group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group LT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Laryngeal Tube Suction IITM group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol Fresenius</intervention_name>
    <description>final dose of Propofol (mcg/kg) to reach the target effect-site concentration</description>
    <arm_group_label>Group IG</arm_group_label>
    <arm_group_label>Group LT</arm_group_label>
    <arm_group_label>Group PS</arm_group_label>
    <arm_group_label>Group SP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA physical status I-III patients.&#xD;
&#xD;
          -  Patients 18-70 years old .&#xD;
&#xD;
          -  Patients scheduled for general anesthesia for elective non-cardiac surgery with SGA&#xD;
             devices.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults with a potentially difficult airway (cervical spine disease, Mallampati&#xD;
             classification IV, or a mouth opening less than 2.5 cm.).&#xD;
&#xD;
          -  Adults with reactive airway disease.&#xD;
&#xD;
          -  Adults with signs of respiratory infection or a plan to remain intubated were excluded&#xD;
             from the study.&#xD;
&#xD;
          -  Excluded patients who had a risk of gastric aspiration or morbid obesity (body mass&#xD;
             index &gt; 35 kg/m2).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Price of Songkla University</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Nalinee Kovitwanawong</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Target Controlled Infusion</keyword>
  <keyword>Supraglottic airway device</keyword>
  <keyword>Propofol</keyword>
  <keyword>Supreme™</keyword>
  <keyword>ProSeal™</keyword>
  <keyword>I-gel™</keyword>
  <keyword>Laryngeal Tube Suction II™</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

